Trevena News
7/14/10 Trevena Secures $35 Million in Series B Funding
Trevena Secures $35 Million in Series B Funding to Progress Portfolio of GPCR Biased Ligands and to Complete Phase 2 Study of TRV120027 for Acute Heart Failure
+ read more
6/11/10 Trevena Data Showcasing GPCR Biased Ligands Featured at Scientific Conferences
Founding Trevena Scientists to Deliver Oral Presentations at World Pharmaceutical Congress and Gordon Research Conference: Phosphorylation & G-Protein Mediated Signaling Networks
+ read more
5/19/10 SCYNEXIS and Trevena Announce Strategic Collaboration to Enhance Discovery of Biased GPCR Ligands
SCYNEXIS, Inc. a drug discovery and development company, and Trevena, Inc., a leader in the discovery and development of G-protein coupled receptor (GPCR) biased ligands, announced today that they have entered into an agreement in which SCYNEXIS will provide medicinal chemistry services to support Trevena’s ongoing research activities directed at the discovery of biased GPCR ligands.
+ read more
4/14/10 Trevena Initiates Clinical Development of TRV120027, a First-in-Class Biased Ligand
Phase 1 Trial Launched to Evaluate Compound for the Treatment of Acute Decompensated Heart Failure
+ read more
2/8/10 Trevena Names David Soergel, M.D. VP, Clinical Development
Trevena Scientific Advisory Board member Dr. John L. LaMattina Wins the Earle B. Barnes Award for Leadership in Chemical Research Management
+ read more
2/3/10 Robert Lefkowitz Honored with 2009 BBVA Award
Robert Lefkowitz Honored with 2009 BBVA Award Trevena Scientific Co-Founder and Scientific Advisory Board Member Honored with 2009 BBVA Foundation Frontiers of Knowledge Award
+ read more
1/26/10 Leadership award for Trevena SAB member, John L. LaMattina
Trevena Scientific Advisory Board member Dr. John L. LaMattina Wins the Earle B. Barnes Award for Leadership in Chemical Research Management
+ read more
11/3/09 Trevena Awarded $7.65 Million NIH Grant
Trevena to Use Innovative Discovery Platform to Identify Novel Biased Ligands and Work with Scientific Research Community to Advance Understanding of New GPCR Pathways and Biology
+ read more
4/27/09 Dr. Robert Ruffolo joins Trevena, Inc. Board of Directors
Trevena, Inc., a specialist GPCR drug discovery company, today announced that Robert Ruffolo has joined its Board of Directors.
+ read more
2/6/09 Ligand Enters into Screening Agreement with Trevena
Ligand Pharmaceuticals Incorporated and Trevena Inc. today announced the initiation of a joint research and license alliance to screen targets using Trevena’s novel biological platform against Ligand’s combinatorial library of compounds.
+ read more
1/7/09 Trevena, Inc. Announces Scientific Advisory Board
Trevena, Inc., a specialist GPCR drug discovery company, today announced that John LaMattina and Robert Ruffolo will join scientific founders Howard Rockman and Robert Lefkowitz on its Scientific Advisory Board.
+ read more
1/5/09 Trevena named one of the "Most Successful US Startups 2008"
Trevena, Inc., a biotechnology company focused on discovery of a new generation of drugs that target G-protein coupled receptors, announced today that BusinessWeek magazine included Trevena in its list of most successful US startup companies of 2008.
+ read more
9/25/08 Trevena, Inc. Founder Honored with National Medal of Science
Dr. Robert Lefkowitz has been awarded the National Medal of Science for his contribution to biology, and will receive the award from President Bush at a White House ceremony on Monday September 29th.
+ read more
3/4/08 Trevena, Inc. Announces $24 Million Series A Financing
Trevena, Inc., a drug discovery company focused on developing pharmaceutical products targeting G-protein coupled receptors (GPCRs), today announced the closing of a $24 million Series A financing.
+ read more
